19.64
-0.47(-2.34%)
Currency In USD
| Previous Close | 20.11 |
| Open | 20.33 |
| Day High | 20.6 |
| Day Low | 19.6 |
| 52-Week High | 21.84 |
| 52-Week Low | 8.21 |
| Volume | 1.83M |
| Average Volume | 1.78M |
| Market Cap | 2.35B |
| PE | -26.9 |
| EPS | -0.73 |
| Moving Average 50 Days | 18.2 |
| Moving Average 200 Days | 15.19 |
| Change | -0.47 |
If you invested $1000 in Arcutis Biotherapeutics, Inc. (ARQT) since IPO date, it would be worth $900.92 as of October 28, 2025 at a share price of $19.64. Whereas If you bought $1000 worth of Arcutis Biotherapeutics, Inc. (ARQT) shares 3 years ago, it would be worth $1,122.29 as of October 28, 2025 at a share price of $19.64.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
GlobeNewswire Inc.
Oct 24, 2025 12:00 PM GMT
New data from Phase 3 studies show once-daily ZORYVE cream helped reduce sleep disruptions in individuals with atopic dermatitis aged ≥2 yearsNew long-term data demonstrate that ZORYVE cream was well-tolerated and provided continued disease control f
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
GlobeNewswire Inc.
Oct 06, 2025 12:00 PM GMT
ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere on the body for any durationAbout 1.8 million child
Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025
GlobeNewswire Inc.
Sep 29, 2025 8:00 PM GMT
WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology, today announced that it will report third quarter 2025 financial